TRAX

41.6406.34%
DM

Dennis M. Fenton

Independent Non-Employee Director

Dr. Dennis M. Fenton, Ph.D., served as Director at Synedgen, Inc. since February 2021. He is a Member of Scientific Advisory Board since February 2019. He serves as a Independent Non-Employee Director at First Tracks Biotherapeutics, Inc. He served as Director at Cirius Therapeutics, Inc. He was Independent Director of AnaptysBio, Inc. since March 5, 2018 until April 20, 2026. He serves as a Director of Modern Meadow, Inc. Dr. Fenton is a Director of Jaguar Health, Inc. since March 19, 2018. He serves as Scientific Advisor of Verdant Therapeutics Inc. Dr. Fenton is the Owner of Fenton and Associates and serves as its Chief Executive Officer. Dr. Fenton served as an Executive Vice President at Operations and Compliance Officer at Amgen Inc. from 2000 until 2008 and was responsible for worldwide operations, manufacturing, process development and quality. Dr. Fenton served as an Executive Vice President at Amgen Inc., from March 2000 to 2008 and served as its Senior Vice President of Operations from January 1995 to March 2000. He served as Senior Vice President of Sales and Marketing at Amgen Inc. from August 1992 to January 1995 and its Vice President of Process Development, Facilities and Manufacturing Services from 1991 to 1992. He also served as Vice President of Pilot Plant Operations and Clinical Manufacturing at Amgen Inc. from October 1988 to July 1991 and served as its Director of Pilot Plant Operations from 1985 to October 1988 and Vice President of Research. Dr. Fenton served as a Senior Research Scientist at Pfizer. He Dr. Fenton began his career as a senior researcher at Pfizer Central in New Product Development from 1977 to 1981. He joined Amgen in 1982 as a Research Scientist. Dr. Fenton coordinated the design, construction and expansion of manufacturing facilities for Epogen(R) (epoetin alfa) and Neupogen(R) (filgrastim). He has been the Chairman of Scientific Advisory Board at Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea, Inc.). since June 2012 and has been its Board Observer since June 2012. Dr. Fenton serves as a Director of Javelin Pharmaceuticals, Inc. He has been a Director at MedImmune Vaccines, Inc. since March 2000. He has been a Director of Cirius Therapeutics, Inc. since December 2017. He has been a Director of Napo Pharmaceuticals, Inc., since May 16, 2011. He served as Director of Nora Therapeutics, Inc. since March 27, 2014. Dr. Fenton is an independent consultant and a member of the boards of directors of Omniox, Inc. He served as Independent Director of Portola Pharmaceuticals, Inc. since February 5, 2015 to July 2020. He was Independent Director of Pfenex Inc. since September 5, 2015 to May 09, 2018. He serves as Member of Science Advisory Board at ImmunGene Inc. He had been a Director at Sienna Biopharmaceuticals, Inc. since October 2016 to December 2019. He was Director of Abzena plc since 2022 until 2025. He serves as a Member of Scientific Advisory Board at Sapphire Energy, Inc. and was Member of Advisory Board at PBS Biotech, Inc. until April 2022. He has been a Member of Scientific Advisory Board at Althea Technologies, Inc. since June 2012. He serves as Director of PBS Biotech, Inc. He serves as a Director at Biotechnology Innovation Organization. He served as a Director of Dendreon Corp. since November 8, 2011. He served as a Director at Hospira Inc. since July 31, 2012. Dr. Fenton served as Director of Kythera Biopharmaceuticals, Inc. (Kythera, Inc.) from June 2006 to October 1, 2015 and served as its Lead Independent Director until October 1, 2015. He served as a Director at Genzyme Corporation since June 2010 and Genelux Corporation since January 24, 2011. He served as a Director at Xenoport, Inc. from August 2009 to July 5, 2016. He served as an Independent Director at Amira Pharmaceuticals, Inc. since April 2008. He served as a Director at CytomX Therapeutics, Inc., since October 2008. Dr. Fenton is a prominent figure in the biotechnology industry and brings extensive experience in various roles such as operations, manufacturing and partnering. Dr. Fenton serves as a Trustee of the Keck Graduate Institute, the Board of Regents of California Lutheran University and Biotechnology Institute. He serves as a Director/Trustee at Rutgers University. Dr. Fenton has a B.S. degree in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

Positions